Kidney health may change how this drug works
NCT ID NCT06814119
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the drug calderasib (MK-1084) behaves in people with moderate or severe kidney problems compared to healthy volunteers. Researchers will measure drug levels in the blood after a single dose to see if kidney function changes how the body processes it. The study also checks for side effects. 34 adults took part, and the results will help guide future dosing for patients with kidney impairment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
calderasib (MK-1084) oral tablet
What this could lead to
If successful, this study could help doctors determine the right dose of calderasib for people with kidney problems, making the drug safer and more effective for them.
What could go wrong
This is a very early (Phase 1) study with only 34 participants, so results may not apply to everyone. It only looks at a single dose, not long-term use, and kidney impairment may affect the drug differently than expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Orlando Clinical Research Center ( Site 0002)
Orlando, Florida, 32809, United States
-
Research by Design ( Site 0001)
Chicago, Illinois, 60643, United States